Friday, 24 April 2015

Foot and Mouth Disease Vaccines Market to Earn Highest Revenues from APAC, to Hit US$ 0.95 billion by 2020

A recent report by Transparency Market Research projects moderate growth within the global foot and mouth disease (FMD) vaccines market through 2020. The report, titled, Foot and Mouth Disease (FMD) Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020, predicts that the FMD vaccines market will chart a CAGR of 8.8% between 2014 and 2020. The FMD vaccines market approximated US$ 0.51 billion as of 2013 and will likely be worth US$ 0.95 billion by 2020, the study finds. The growing frequency of FMD outbreaks has necessitated the development of more effective vaccines to treat the disease; this is especially seen in endemic countries. The disease has been a gnawing concern for governments of several nations, prompting them to allocate more funding to eradicate the foot and mouth disease. The government’s role has helped raise levels of awareness about the foot and mouth disease in general and about the FMD vaccines available in particular, causing a higher demand for routine FMD vaccination.

Browse the full Foot and Mouth Disease Vaccines Market Report at http://www.transparencymarketresearch.com/foot-mouth-disease-vaccines.html

Conversely, the market does face restraints in the form of unpredictable outbreaks of serotype. Governments are purchasing vaccines from private manufacturers, which, to some extent, limits the expansion of the FMD vaccines market.To study the market in detail, the report segments the foot and mouth disease vaccines market by type as: Conventional and emergency vaccines. The conventional FMD vaccines market has been further sub-segmented as: Aluminum hydroxide/saponin, and oil-based vaccines. The oil-based FMD vaccines segment held a 63% share in the overall FMD vaccines market as of 2013 thanks to its efficacy in treating the disease and its prolonged effect on different kinds of animals such as cattle, goat and sheep, and pigs.


The report also studies the market for FMD vaccines based on application types as: Cattle, sheep and goats, pigs, and others. The cattle segment was observed to be the largest application segment in the FMD vaccines market in 2013. This is ascribed to the high number of cattle reared worldwide, especially as the demand for milk and meat reaches unprecedented levels. The demand for FMD vaccines for cattle will be especially high in the Middle East-where pork consumption is prohibited. From the global standpoint as well, the cattle segment will exhibit the highest CAGR through the forecast period of this report.The four regions of North America, Asia Pacific, Europe, and Rest of the World have been studied comprehensively to offer a narrower overview of the regional market dynamics.




The findings of the report state that in 2013, the Asia Pacific region made up a whopping 70% share of the global FMD vaccines market. A high number of FMD endemic countries are present in this region, and outbreaks of FMD are still frequent here. Governments have been actively involved in the eradication of FMD diseases from their respective countries. Australia and New Zealand are exceptions to this because though they lie within the APAC region, the FMD disease is virtually non-existent here. Western Europe and North America are other geographical zones that are free of the FMD disease, which indicates practically no scope for the growth of the FMD disease market here.
The TMR report profiles FMD vaccine industry players such as Bayer AG, Agrovet Co., Brilliant Bio Pharma Limited, Biogenesis Bagó, and Indian Immunologicals Ltd.



About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Meningococcal Vaccines Market Expected to Reach USD 4.4 Billion Globally in 2022

According to a new report published by Transparency Market Research “Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022,” the meningococcal vaccines market was valued at USD 1.5 billion in 2013 and is expected to reach a value of USD 4.4 billion in 2022, growing at a CAGR of 12.4% from 2014 to 2022.

Browse the full Meningococcal Vaccines Market Report at http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html


Meningococcal disease is caused by the bacterium Neisseria meningitidis and occurs sporadically throughout the world with seasonal variations. It accounts for a proportion of endemic bacterial meningitis, which can progress very rapidly leading to death within 24 hours from the onset of symptoms. The disease is often misinterpreted as common flu in most of the cases. Five out of the several serogroups are known to cause meningococcal disease. The serogroups responsible for causing the disease comprise A, B, C, Y and W-135. The causative agent N. meningitidis is commonly found in the nasopharynx of humans and gets transmitted through droplet inhalation by means of close contact such as exposure to smokers, crowded living conditions such as dormitories, certain inherited disorders of the immune system, functional/anatomical asplenia or through intimate oral contact among others. According to the European Federation of Pharmaceutical Industries and Association, every year, meningitis affects almost 500,000 people globally, primarily affecting toddlers, infants and young adults, due to weaker immune system.

The global market for meningococcal vaccines is segmented broadly into vaccine types namely, polysaccharide, conjugate, combination and Men B vaccines. The report also provides analysis for vaccine under development, NmVac4-DT by JN- International that is expected to be commercialized during the forecast period 2014 to 2022. The vaccine types are further segmented by different brands available in the market. The conjugate vaccines segment is likely to lead the overall meningococcal vaccines market in terms of revenue, which is estimated to be worth USD 2,655.0 million by 2022 at a CAGR of 8.9%. According to Department of Health, U.K., Bexsero is the first serogroup B vaccine to be incorporated into the national immunization program and is expected to be available in the market for sales post settle of price negotiations. The U.S. FDA recently approved two Men B vaccines: Trumenba by Pfizer in October 2014 and Bexsero by Novartis in January 2015.

Browse the full Press release Report :

The market for meningococcal vaccines is largely driven by increasing government intervention in reforming the healthcare infrastructure and incorporation of legislations specific to meningococcal vaccination. The public-private partnerships for conducting research and development, and manufacturing of quality vaccines at an affordable price are also contributing positively in driving market growth. Awareness campaigning from government and non-profit organizations, and obligatory immunization for individuals heading to Mecca (for Hajj pilgrimage) and the South African meningitis belt will also contribute to growth of this market. High cost of few but vital vaccines, such as Bexsero, and need for efficient cold chain logistics to maintain safety and efficacy of the vaccine are expected to be some of the major factors posing a challenge to the adequate uptake of these vaccines.

meningococcal-vaccines-market


The key players dominating the global meningococcal vaccines market include Sanofi Pasteur (the vaccine division of Sanofi SA), Novartis International AG and GSK plc. These players account for more than 90% of the meningococcal vaccines market. Players such as Serum Institute of India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd., Nuron Biotech and Baxter account for the remaining market share.

The global meningococcal vaccines market is segmented as follow:

Meningococcal Vaccines Market, by Type
Polysaccharide Vaccines, by Brand
Menomune
Mencevax
NmVac4
Others
Quadri Meningo
Bi Meningo
Conjugate Vaccines, by Brand
Menactra
Menveo
NeisVac-C
Nimenrix
Meningitec
Menjugate
MenAfriVac
Combination Vaccines, by Brand
MenHibrix
Menitorix
NmVac4-DT
Men B Vaccines, by Brand
Bexsero
Trumenba
Meningococcal Vaccines Market, by Geography
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia Pacific
Japan
Australia
Rest of Asia Pacific
Rest of the World
Latin America
Africa
Rest of RoW


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.